Semax

5mg Vial

10mg Vial

29 August 2026Updated 29 August 2026

Semax

Overview Research0 Mechanism Protocols Safety

Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for Semax.

Create free account Member login

Full range of benefits for Semax

Supports cognitive function: memory, attention, and learning

Has shown neuroprotective effects in ischemia and stroke studies

May increase neurotrophin expression (BDNF, NGF) in the brain

May modulate monoamine neurotransmission (dopamine, serotonin)

May reduce neuroinflammation and oxidative stress in CNS models

May improve cerebral blood flow and brain energy metabolism

May support recovery after stroke or traumatic brain injury

Formulated for intranasal delivery for rapid CNS access

Designed to lack systemic endocrine activity of full ACTH peptides

Shows anxiolytic and antidepressant-like effects in preclinical studies

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 12 known interactions

Synergistic(3)Compatible(3)Monitor(3)Avoid(3)

Not recommended for concurrent use

Monoamine oxidase inhibitors (MAOIs)

Exercise caution because combined modulation of monoaminergic tone may theoretically increase risk of hypertensive or neuropsychiatric events, warranting specialist review.

Central nervous system stimulants (amphetamine, methylphenidate)

Caution advised for potential additive CNS stimulation and cardiovascular effects (blood pressure, heart rate) when used with Semax-enhanced arousal or monoaminergic activity.

History of epilepsy or concurrent proconvulsant medications

Carefully evaluate seizure risk because Semax influences glutamatergic and neurotrophic pathways and may alter seizure threshold in susceptible individuals.

All interaction categories

Synergistic (3)

Citicoline (CDP-choline): Enhances membrane phospholipid synthesis and neurorepair pathways and is frequently combined with Semax to augment post-stroke cognitive recovery and neurorestoration.
Piracetam: A nootropic agent that modulates neuronal membrane function and cognition and can potentiate Semax's cognitive and neuroprotective effects in cognitive impairment syndromes.
Vinpocetine: A cerebrovasodilator and neuroprotective compound that may complement Semax by improving cerebral perfusion and enhancing overall neuroprotective benefit.

Compatible (3)

Paracetamol (acetaminophen): Analgesic/antipyretic with no expected pharmacodynamic or pharmacokinetic interaction when administered concomitantly with intranasal Semax.
Standard antihypertensives (ACE inhibitors / ARBs): Commonly co-prescribed in cerebrovascular populations and generally show a neutral co-administration profile with Semax without routine dose adjustment.
Statins (e.g., atorvastatin): Lipid-lowering agents used in stroke prevention that have no known direct interaction with Semax and are typically safe for concurrent use.

Monitor (3)

Selective serotonin reuptake inhibitors (SSRIs) / SNRIs: Monitor mood, behavior and blood pressure because Semax can modulate neurotrophic and monoaminergic systems and additive central effects or behavioral changes may occur.
Anticoagulants and antiplatelet agents (warfarin, DOACs, aspirin): Monitor for bleeding complications and INR (where applicable) when combining with Semax in post-stroke or vascular patients due to polytherapy and overlapping clinical risk profiles.
Antihypertensive therapy: Monitor blood pressure and clinical status during initiation or dose changes because Semax influences cerebral hemodynamics and autonomic regulation in some patients.

Avoid (3)

Monoamine oxidase inhibitors (MAOIs): Exercise caution because combined modulation of monoaminergic tone may theoretically increase risk of hypertensive or neuropsychiatric events, warranting specialist review.
Central nervous system stimulants (amphetamine, methylphenidate): Caution advised for potential additive CNS stimulation and cardiovascular effects (blood pressure, heart rate) when used with Semax-enhanced arousal or monoaminergic activity.
History of epilepsy or concurrent proconvulsant medications: Carefully evaluate seizure risk because Semax influences glutamatergic and neurotrophic pathways and may alter seizure threshold in susceptible individuals.